GSK reveals significant Shingrix vaccine efficacy in ZOSTER-049 trial

GSK plc announced the results of the ZOSTER-049 phase III long-term follow-up trial, showcasing that the Shingrix (Recombinant Zoster Vaccine or RZV) maintains high efficacy ... Read More